The overuse and misuse of antibiotics and the adaptability of microbes has created a problem that people must solve: common antibiotics are not as effective as they used to be. Researchers have to ...

An international team of researchers, led by the University of Vienna and the Helmholtz Institute for Pharmaceutical Research Saarland, has discovered saarvienin A, a new type of glycopeptide ...

Scientists from the University of Tübingen and Monash University studied glycopeptide antibiotics, a key resource in countering drug-resistant pathogens, to uncover their evolutionary origins to gain ...

IFLScience needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time.

LONDON, July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announced the approval of a novel formulation of the first-of-its-kind, ready-to ...

Antibiotic resistance is a tough problem—one some biologists worry cannot be solved with a business-as-usual approach to drug development. So researchers led by Gerard D. Wright at McMaster University ...

Hikma has obtained permission from the Food and Drug Administration for a novel formulation of the first-of-its-kind, ready-to-infuse formulation of vancomycin, under the brand name Tyzavan ...

Adding vancomycin to beta-lactam prophylaxis with cefazolin did not help prevent surgical-site infections in patients undergoing arthroplasty mostly for the knees or hips, a randomized trial showed.